Results 251 to 260 of about 1,014,675 (337)

Harnessing the Neurobiology of Empathy and Compassion to Alleviate Burnout in Neurology

Annals of Neurology, EarlyView.
The neurologist cares for patients with complex chronic conditions that compromise their wellbeing. Many such disorders are poorly understood. Whereas for some, effective symptomatic treatments exist, for most we lack an understanding of the molecular and cellular bases for disease pathogenesis needed for discovering disease‐modifying treatments ...
Fadel Zeidan, Joseph D. Stern, William C. Mobley   +2 more
wiley   +1 more source

Correction: Metabolic resilience: liraglutide's potential in alleviating depressive symptoms. [PDF]

Mol Biol Rep
Gammoh O, Qnais E, Aljabali AAA, Hatahet T, Alqudah A.   +4 more
europepmc   +1 more source

Associations Between Changes in Pain Sensitization and Disease Activity Following Disease‐Modifying Antirheumatic Drug Therapy in Established Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Abnormalities in pain regulatory mechanisms are common in patients with rheumatoid arthritis (RA). We investigated whether pain sensitization changes after treatment with a disease‐modifying antirheumatic drug (DMARD) and explored associations between changes in pain sensitization and disease activity.
Burcu Aydemir, Andrew C. Heisler, Lutfiyya N. Muhammad, Jing Song, Alyssa Wohlfahrt, Daniel J. Clauw, Wendy Marder, Marcy B. Bolster, Clifton O. Bingham, Tuhina Neogi, Yvonne C. Lee   +10 more
wiley   +1 more source

Objective speech measures capture depressive symptoms and associated cognitive difficulties. [PDF]

Transl Psychiatry
Wiseman M, Yep R, Wood Alexander M, Pople CB, Perri L, Gopinath G, Vasileiadi M, Robin J, Spilka MJ, Simpson W, Yunusova Y, Munoz DP, Coe BC, Brien D, Nestor S, Lipsman N, Giacobbe P, Rabin JS.   +17 more
europepmc   +1 more source

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...
Carol A. Langford, Nader Khalidi, Jason Springer, Marcia Friedman, Bernhard Hellmich, Christian Pagnoux, Natasha Dehghan, Ora Gewurz‐Singer, Curry L. Koening, Yih Chang Lin, Paul A. Monach, Larry W. Moreland, Aurore Fifi‐Mah, Oliver Flossmann, Lindsy J. Forbess, Peter Lanyon, Eamonn Molloy, Ulrich Specks, Robert Spiera, Elaine Yacyshyn, Carol A. McAlear, Cristina Burroughs, Rachel B. Jones, Rennie L. Rhee, Rula Hajj‐Ali, Kenneth J. Warrington, David Cuthbertson, Jeffrey P. Krischer, David Jayne, Peter A. Merkel, for the Vasculitis Clinical Research Consortium and the European Vasculitis Society, Eric Stratton, Marcin Trojanowski, Chris Zammitti, Jessica Ziemek, Javier Ache, Marianne Bernardo, Bryan Gonzalez, Mariko Ishimori, Bonnie Paul, Mahbuba Tusty, Swamy Venuturupalli, Daniel Wallace, Michael Weisman, Debora Bork, Tiffany Clark, Sonya Crook, Kathleen Gartner, Lori Strozniak, Elizabeth Kisela, Marcia Leon, Loretta Williams, Jeff Negrey, Hannah Thome, Andrew Wiecek, Beemnet Amdemicael, Emily Bakaj, Aliza Bloostein, Annel Fernandez, Chris Hatzis, Lindsay Lally, Misbah Baqir, Cynthia Beinhorn, Shannon Daley, Sue Donlinger, Samantha Fatis, Yeoniee Kim, Matthew Koslow, Matthew J. Koster, Kathleen Mieras, Tobias Peikert, Michael Stachowitz, Gwen E. Thompson, Medius Klinik Kirchheim, Nicole Hollinger, Nina Kempiners, Hartmut Mahrhofer, Anke Reichelt de Tenorio, Bastian Walz, Banita Aggarwal, Simon Carette, Nazrana Haq, Samyukta Jagadeesh, Suneet Khurana, Judy Vendramini, Amanda Butler, Mithun Chakravorty, Paige Draper, Cattleya Godsave, Marie‐Josèphe Pradère, Megan Rutter, Alan Thomas, Rebekah Alexander, Cong‐Qiu Chu, Daniela Ghetie, Amy Jeon, Michelle Jin, Kim Phung Nguyen, Brenda Olmos, Kelly Peel, Rosy Quinn, Cailin Sibley, Mayamol Joseph, Deepa Thapa, Sandra Messier, Diane Robins, Jayamarx Jayaraman, Kam Shojania, Richard Conway, Kathy Brickell, Phil Gallagher, Alison Clifford, Sylvia Gaucher, Ainslie Hildebrand, Karen Martins, Breanne Stewart, Stephen Chaudary, Namneet Sandhu, Stephen Williams, Karen Dahlsveen, Seerapani Gopaluni, Cecilia Matara, Mark McClure, Rona Smith, Amrita Bath, Leslie Glasco, Theresa Howard, Caitlin McMillian, Na Yu, Mingcai Zhang, Ruba Kado, Emily Lewis, W. Joseph McCune, Emily Siegwald, Jennifer Sylvester, Naomi Amudala, Kathryn Doyle, Matthew MacDonald, Leah Madden, Brian Rice, Antoine Sreih, Sally Thompson, Laurie Hope, Kimberly Liang, Douglas Lienesch, Niveditha Mohan, Kelly Reckley, John Carter, Gail Lewis, Michelle Orzechowski, Martha Finco, Jennifer Godina, Jessica Gonzalez, Julieanne Hall, Nereida Ortez, Gopi Penmetsa   +155 more
wiley   +1 more source

Esketamine for Postoperative Depressive Symptoms: Considerations for Broader Perioperative Practice [Letter]. [PDF]

Drug Des Devel Ther
Matthewson L.
europepmc   +1 more source

Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Rheumatoid arthritis is a complex systemic disorder characterised primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease e.g. of the lung with potentially devastating clinical consequences.
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

College nursing students' prevalence of depressive symptoms and associated factors: A cross-sectional study. [PDF]

Medicine (Baltimore)
Alreshidi SM.
europepmc   +1 more source

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

Executive functioning moderates the relationship between motivation and adolescent depressive symptoms

, 2012
Chrystal Vergara‐Lopez, Hector I. Lopez-Vergara, Craig R. Colder   +2 more
openalex   +2 more sources